医药生物行业周报：继续把握估值切换，市场风险偏好提升优选中小创个股
DONGXING SECURITIES 敬请参阅报告结尾处的免责声明 东方财智 兴盛之源 行业研究 东兴证券股份有限公司证券研究报告 DONGXING SECURITIES 东兴证券行业周报（20170904-20170910） 生物医药行业：继续把握估值切换，市场风险偏好提升优选中小创个股 P3 敬请参阅报告结尾处的免责声明 东方财智 兴盛之源 1. ............................................................................................................................................................................... 4 1.1 ........................................................................................................................................................................................ 4 1.1.1 ............................................................................................................................................................. 4 1.1.2 ..................................................................................................................................................... 8 1.1.3 ..................................................................................................................................................................... 9 1.2 ...................................................................................................................................................................................... 11 1.2.1 ........................................................................................................................................................... 11 1.2.2 ...........................................................................................................................................................12 1.3 ..............................................................................................................................................................................14 2. .........................................................................................................................................................................................16 2.1 ..................................................................................................................................................................................16 2.2 ......................................................................................................................................................................................19 2.3 ..................................................................................................................................................................................19 3. .........................................................................................................................................................................................21 4. .....................................................................................................................................................................................25 4.1 ..................................................................................................................................................25 5. .................................................................................................................................................................................................29 P4 东兴证券行业周报（20170904-20170910） 生物医药行业：继续把握估值切换，市场风险偏好提升优选中小创个股 DONGXING SECURITIES 敬请参阅报告结尾处的免责声明 东方财智 兴盛之源 1: .........................................................................................................................................................10 2: .........................................................................................................................................................10 3: .................................................................................................................... ! 1:2017vs.300vs......................................................................................... 5 2:2017 ................................................................................................. 5 3:%........................................................................................................ 7 4:%............................................................................................ 7 5:%................................................................................................................................................ 8 6:%............................................................................................................................................ 9 7:TTM ............................................................................................................................. 11 8:vs.A .............................................................. 11 9:vs.A ..................................................12 10:TTM ...................................................................................................................13 11:TTM ..........................................................................................
